** Shares of Israel-based medical device maker IceCure Medical ICCM.O rise 8.11% to 79 cents premarket
** A panel of experts to the FDA supported the use of IceCure's system when used according to the proposed indications for the treatment of patients with a type of breast cancer
** ICCM's ProSense provides a minimally invasive treatment option to destroy tumors by freezing them
** 9 panelists voted in favor and 5 voted against the benefit-risk profile of the system
** FDA is not obligated to follow the panel's decision, but usually does
** Co expects FDA's decision by Q1 2025
** Up to last close, stock down ~31% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。